The Sistema Group company, Binnopharm Group, one of Russia’s leading pharmaceutical production companies via its affiliate joint-stock company’ Alium’, and Dr. Reddy’s Laboratories, an integrated global pharmaceutical company, on 21 February 2022, announced the signing of a deal would allow Binnopharm Group to acquire anti-bacterial medicines under the Ciprolet and Levolet brands from Dr. Reddy’s in Russia, Uzbekistan and Belarus. The portfolio includes various dosage forms such as tablets, solutions for infusions and eye drops.
Rustem Muratov, chief executive officer of the Binnopharm said, “The acquisition of Ciprolet and Levolet is an important step to enhance our position in the antibiotics market, one of the key market segments for Binnopharm Group. According to independent analyst estimation, these strong brands have already had the trust of millions of consumers – according to independent analyst estimation, they are leaders in their market segments. They will be a valuable complement to our portfolio of anti-bacterial products. We are also acquiring rights to these products in Belarus and Uzbekistan in line with our strategic goal to strengthen presence in the international markets.”
MV Ramana, chief executive officer – Branded Markets (India and emerging markets), said, “Our Russia and CIS markets continue to be strong performers for the company. This deal is a step towards divesting brands in non-core areas to further consolidate and strengthen our play in our key focus therapy areas of gastro-enterology, pain management, cold and flu, allergy, oncology, neurology, paediatrics, etc and women’s health. This will help us accelerate access to affordable and innovative medicines in the region in these segments in keeping with our purpose of ‘Good Health Can’t-Wait‘.”
During the transition period, Dr. Reddy’s will continue to supply the product to Binnopharm Group to ensure availability in the market.
